<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Rep Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Case Rep Psychiatry</journal-id><journal-id journal-id-type="publisher-id">CRIPS</journal-id><journal-title-group><journal-title>Case Reports in Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">2090-682X</issn><issn pub-type="epub">2090-6838</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26000191</article-id><article-id pub-id-type="pmc">4427013</article-id><article-id pub-id-type="doi">10.1155/2015/542862</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Three Patients Needing High Doses of Valproic Acid to Get Therapeutic Concentrations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jackson</surname><given-names>James</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>McCollum</surname><given-names>Betsy</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ognibene</surname><given-names>Judy</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Diaz</surname><given-names>Francisco J.</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>de Leon</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Psychiatry, College of Medicine, University of Kentucky, Lexington, KY 40509, USA</aff><aff id="I2"><sup>2</sup>Pharmacy, Eastern State Hospital, Lexington, KY 40511, USA</aff><aff id="I3"><sup>3</sup>Apalachee, Inc., Eastside Psychiatric Hospital, Tallahassee, FL 32308, USA</aff><aff id="I4"><sup>4</sup>Department of Biostatistics, The University of Kansas Medical Center, Kansas City, KS 66160, USA</aff><aff id="I5"><sup>5</sup>University of Kentucky Mental Health Research Center, Eastern State Hospital, Lexington, KY 40511, USA</aff><author-notes><corresp id="cor1">*Jose de Leon: <email>jdeleon@uky.edu</email></corresp><fn fn-type="other"><p>Academic Editor: Liliana Dell'Osso</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>27</day><month>4</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>542862</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>8</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 James Jackson et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Valproic acid (VPA) can autoinduce its own metabolism. Cases requiring VPA doses &#x0003e;4000&#x02009;mg/day to obtain therapeutic plasma concentrations, such as these 3 cases, have never been published. Case 1 received VPA for seizures and schizophrenia and had &#x0003e;50 VPA concentrations in 4 years. A high dose of 5,250&#x02009;mg/day of VPA concentrate was prescribed for years but this dose led to an intoxication when switched to the enterocoated divalproex sodium formulation, requiring a normal dose of 2000&#x02009;mg/day. VPA metabolic capacity was significantly higher (<italic>t</italic> = &#x02212;9.6; df = 6.3, <italic>p</italic> &#x0003c; 0.001) during the VPA concentrate therapy, possibly due to autoinduction in that formulation. Case 2 had VPA for schizoaffective psychosis with 10 VPA concentrations during an 8-week admission. To maintain a VPA level &#x02265;50&#x02009;<italic>&#x003bc;</italic>g/mL, VPA doses increased from 1500 to 4000&#x02009;mg/day. Case 3 had tuberous sclerosis and epilepsy and was followed up for &#x0003e;4 years with 137 VPA concentrations. To maintain VPA concentrations &#x02265;50&#x02009;<italic>&#x003bc;</italic>g/mL, VPA doses increased from 3,375 to 10,500&#x02009;mg/day. In Cases 2 and 3, the duration of admission and the VPA dose were strongly correlated (<italic>r</italic> around 0.90; <italic>p</italic> &#x0003c; 0.001) with almost no change after controlling for VPA concentrations, indicating progressive autoinduction that increased with time.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Valproic acid (VPA) is a classic antiepileptic drug (AED) and has been a major pharmaceutical tool in the management of a range of psychiatric and neurological diseases since the 1960s [<xref rid="B1" ref-type="bibr">1</xref>]. VPA is currently approved in the US for the treatment of several types of epilepsy, bipolar disorder, and migraine prophylaxis. The maximum recommended doses for epilepsy or bipolar disorder are 60&#x02009;mg/kg/day [<xref rid="B2" ref-type="bibr">2</xref>]. It is rare to see patients taking &#x0003e;4000&#x02009;mg/day. Moreover, therapeutic drug monitoring (TDM) is frequently used to establish and track VPA doses. Neurologists frequently use a therapeutic range of 50&#x02013;100&#x02009;<italic>&#x003bc;</italic>g/mL for epilepsy [<xref rid="B3" ref-type="bibr">3</xref>]. The therapeutic range in bipolar disorder is not very well established but some reviews recommend up to 125&#x02009;<italic>&#x003bc;</italic>g/mL for mania [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>In spite of decades of use, VPA metabolism is not completely understood [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. VPA primarily undergoes hepatic metabolism, while &#x0003c;5% is eliminated and unchanged in the urine. The major mechanisms of hepatic metabolism are the uridine diphosphate glucuronosyltransferases (UGTs; 40%) and <italic>&#x003b2;</italic>-oxidation as a fatty acid (30%), with the cytochrome P450 (CYP; including CYP2C9, CYP2C19, and CYP2A6) as a minor component in the metabolic process. At low doses, <italic>&#x003b2;</italic>-oxidation may be the most important pathway, while at therapeutic doses glucuronidation may be more important [<xref rid="B3" ref-type="bibr">3</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. Many UGTs appear to be involved in valproate glucuronidation including UGT1A3, UGT1A4, UGT1A6, UGT1A9, and UGT2B7, along with the primarily intestinal UGT1A8 and UGT1A10 [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>Regarding the potential of causing drug-drug interactions (DDIs), VPA was traditionally considered to be a moderate inhibitor of several enzymes including CYP2C9, epoxide hydroxylase, several UGTs, and the N-glucosidation pathway of phenobarbital [<xref rid="B4" ref-type="bibr">4</xref>]. First, rat studies suggested that VPA may autoinduce its own glucuronidation [<xref rid="B10" ref-type="bibr">10</xref>]. The first clinical suggestions that VPA may autoinduce its own metabolism were from studies focused on felbamate [<xref rid="B11" ref-type="bibr">11</xref>] and lamotrigine [<xref rid="B12" ref-type="bibr">12</xref>]. More recent studies have been able to demonstrate that VPA induces (1) its own metabolism by inducing <italic>&#x003b2;</italic>-oxidation (prospective study) [<xref rid="B13" ref-type="bibr">13</xref>]; (2) CYP3A4 and P-gp gene expression (in vitro study) [<xref rid="B14" ref-type="bibr">14</xref>]; (3) possible UGT1A1 in a patient taking irinotecan (which has an active metabolite, SN-38, metabolized by UGT1A1) [<xref rid="B15" ref-type="bibr">15</xref>]; (4) aripiprazole metabolism to a mild degree (prospective study) [<xref rid="B16" ref-type="bibr">16</xref>]; (5) olanzapine metabolism (case series [<xref rid="B17" ref-type="bibr">17</xref>], TDM [<xref rid="B18" ref-type="bibr">18</xref>], a statistical model of TDM-DDI studies [<xref rid="B19" ref-type="bibr">19</xref>], and a prospective DDI study) [<xref rid="B20" ref-type="bibr">20</xref>]; (6) clozapine metabolism (case series [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>], a prospective case report [<xref rid="B23" ref-type="bibr">23</xref>], and statistical models of TDM-DDI studies [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]); and (7) vitamin D metabolism in an in vitro study [<xref rid="B26" ref-type="bibr">26</xref>]. In summary, VPA may be like other AEDs, such as oxcarbazepine or topiramate, and act as a mild inducer for some metabolic enzymes and behave as a clinically relevant inhibitor of other metabolic enzymes.</p><p>The following 3 cases, accumulated by the senior author in the last 20 years of his clinical practice, describe 3 patients needing high doses of VPA to reach and maintain therapeutic concentrations &#x02265;50&#x02009;<italic>&#x003bc;</italic>g/mL. Recent advances in pharmacokinetic knowledge have allowed us to offer a hypothesis about these patients' needs for such high VPA doses to reach therapeutic concentrations. On February 19, 2015, we conducted a PubMed search using the words &#x0201c;valproic acid and (high dose or high dosage)&#x0201d; limiting them to title or abstract, human participants, and case reports, which provided 33 articles. None of these 33 articles described the therapeutic use of VPA doses &#x0003e;4000&#x02009;mg/day. We decided to publish these cases because it is very likely that other clinicians have seen similar patients but did not write about them.</p></sec><sec id="sec2"><title>2. Methods</title><sec id="sec2.1"><title>2.1. Clinical Setting</title><p>The senior author collected these 3 cases during the last 20 years while working as a clinician and/or consultant in the public mental health system in Kentucky, USA. During 8 of those years, he managed a 30-bed treatment-refractory unit for psychotic patients in a state hospital with approximately 1600 admissions/year. He acquired Cases 1 and 3 in that setting. For 14 years he has also acted as a consultant for difficult cases, including those needing high doses of psychiatric medications in 4 state hospitals for severe mentally ill patients, 4 hospitals for adults with intellectual disabilities, and 2 nursing homes. Case 2 was collected as a consultant for another psychiatrist (third author). In the senior author's experience, VPA is probably the most frequently prescribed psychotropic drug in the public mental health system facilities of Kentucky, with more than 1000 patients every year treated with VPA at state facilities. The 3 patients in this paper participated in pharmacogenetic studies after written informed consent forms were signed by them and/or their guardians.</p></sec><sec id="sec2.2"><title>2.2. TDM</title><p>These 3 cases contain TDM information that was collected for clinical purposes many years ago. The VPA TDM was done by immunoassay in the same psychiatric hospital using the same clinical laboratory at the hospital; levels were taken as trough concentrations (early AM before taking medications) and after reaching steady state. The VPA concentrations were measured in <italic>&#x003bc;</italic>g/mL, which is the same as mg/L.</p><p>In the last 10 years, the senior author has increasingly used the pharmacological concept of concentration-to-dose ratio (C/D ratio) to study TDM in order to personalize the prescription of psychiatric medications in psychopharmacology. The C/D ratio is a measure of the ability to eliminate the drug and is influenced by genetic, personal, and environmental factors. Inducers decrease the C/D ratio and inhibitors increase the C/D ratio. In comparing individuals taking the same drug, a very low C/D ratio indicates an individual with very fast metabolism, while a very high C/D ratio indicates one with very slow metabolism. Each drug is different and unique and has its own normal ranges for C/D ratios determined by its own bioavailability and elimination from the body.</p><p>The senior author has used the C/D ratio to interpret TDM of clobazam [<xref rid="B27" ref-type="bibr">27</xref>], clozapine, and risperidone [<xref rid="B28" ref-type="bibr">28</xref>]. These 3 drugs, like the majority of drugs used in neuropsychopharmacology, follow linear kinetics. A linear relationship exists between typical doses and plasma concentrations. This means that the relationship between concentration and dose is stable; it does not change with different doses and concentrations, and the drug C/D ratio is constant in the same patient as long as there are no changes in environmental or personal variables.</p><p>VPA TDM, unfortunately, is a little more complicated since it does not follow linear kinetics. The relationship between VPA dose and total concentration is nonlinear; the concentration does not increase proportionally with the dose but increases to a lesser extent due to saturable plasma-protein binding [<xref rid="B29" ref-type="bibr">29</xref>]. As the VPA C/D ratio is not constant and changes with different doses and concentrations, one needs to further interpret VPA C/D ratios in the context of a set of concentrations or set of doses.</p><p>The senior author has started using VPA C/D ratios in his teaching and clinical practice in the last 3 years and is not aware of any published article using them. Therefore, as the reader may not be familiar with the use of C/D ratios for valproate VPA, this section provides a short introduction. Based on experience as a lecturer, the senior author has figured out that VPA C/D ratios have values too low to be easily understood by physicians, who do not tend to be particularly strong in mathematics. To more easily understand the VPA C/D values, they are also presented with a value obtained by multiplying by 1000. To understand this, let us assume that a VPA dose of 2000&#x02009;mg/day provides a total VPA concentration of 100&#x02009;<italic>&#x003bc;</italic>g/mL. Therefore the C/D ratio in this patient is 100/2000 or 0.05. The C/D ratio multiplied by 1000 would be 50, an easier number to grasp.</p><p>Next, we can use a published case of VPA toxicity [<xref rid="B29" ref-type="bibr">29</xref>] to explain the interpretation of VPA C/D ratio for clinical use. To simplify, <xref ref-type="table" rid="tab1">Table 1</xref> presents only the VPA data including C/D ratios using total VPA concentrations. This patient has relatively narrow variations, with a C/D ratio multiplied by 1000 ranging between 112 and 132 (<xref ref-type="table" rid="tab1">Table 1</xref>). These values are normal in the experience of the senior author. Moreover, these values follow the usual pattern of VPA C/D ratios. In low doses, in this case 500&#x02009;mg/day, the C/D ratio multiplied by 1000 ranged from 128 to 132. In high doses, in this case 1000&#x02009;mg/day, the C/D ratio multiplied by 1000 was 112, indicating a faster metabolism at 1000&#x02009;mg/day than at the 500&#x02009;mg/day dose. At higher VPA doses, plasma proteins such as albumin are saturated by VPA and the percentage of free (unbound) VPA concentration increases. Since free VPA is the entity that is metabolized, the higher the percentage of free concentration is, the faster the VPA is metabolized. In the experience of the senior author, approximately 90% of VPA on average is carried by plasmatic proteins and 10% is free at standard therapeutic concentrations. With higher concentrations, the relative concentrations of free VPA increase (e.g., 85% bound and 15% free), and with low concentrations it decreases (e.g., 95% bound and 5% free). These percentages of free VPA concentration are also influenced by (1) the plasma concentration of albumin and other plasmatic proteins, (2) plasma concentrations of some endogenous compounds that may bind to the proteins (e.g., bilirubin), and (3) the presence of other drugs (e.g., aspirin), which may also compete for plasmatic protein binding [<xref rid="B29" ref-type="bibr">29</xref>].</p><p>Other examples of VPA C/D ratio are calculated using published data [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. A case [<xref rid="B30" ref-type="bibr">30</xref>] of a possible VPA adverse drug reaction (ADR) occurred in a patient who had a VPA concentration 78&#x02009;<italic>&#x003bc;</italic>g/mL at a dose of 1500&#x02009;mg/day (C/D ratio = 0.520 calculated by 78/1500). The VPA C/D ratio multiplied by 1000 was 520. In a study of VPA TDM [<xref rid="B31" ref-type="bibr">31</xref>], 14 females had an average VPA concentration of 76&#x02009;<italic>&#x003bc;</italic>g/mL with an average maintenance dose of 629&#x02009;mg/day (C/D ratio = 0.121 calculated by 76/629) and a VPA C/D ratio multiplied by 1000 of 121. In the same study, 23 males had an average VPA concentration of 70&#x02009;<italic>&#x003bc;</italic>g/mL with an average maintenance dose of 617&#x02009;mg/day (C/D ratio = 0.113 calculated by 70/617) with a VPA C/D ratio multiplied by 1000 of 113.</p><p>These 3 cases needing VPA doses &#x0003e;4000&#x02009;mg/day to obtain VPA therapeutic concentrations had very low mean C/D ratios multiplied by 1000: in the 20s or lower, possibly due to VPA autoinduction.</p></sec><sec id="sec2.3"><title>2.3. Scale</title><p>For this paper, we have completed the Drug Interaction Probability Scale (DIPS) [<xref rid="B32" ref-type="bibr">32</xref>] for each of the 3 cases.</p></sec><sec id="sec2.4"><title>2.4. Statistics</title><p>Available data for each of the 3 cases was dictated by clinical care; many years later we tried to use statistical techniques to accommodate the available data and the questions asked in each case. The Statistical Package for the Social Sciences (SPSS 22) was used to analyze the data. In Case 1 an independent sample <italic>t</italic>-test compared mean VPA C/D ratios from the two VPA formulations, one probably accompanied with autoinduction and the other not. Pearson correlations between VPA dose and day of admission were used in Cases 2 and 3 to demonstrate that higher doses were needed to keep the VPA concentrations therapeutic over time, which is consistent with a pattern of autoinduction. Partial correlations were used to demonstrate that VPA concentrations did not explain the correlation between VPA dose and day of admission.</p></sec></sec><sec id="sec3"><title>3. Case Presentations</title><sec id="sec3.1"><title>3.1. Case 1</title><p>A Caucasian male was followed up for more than 4 years between the ages of 30 and 34 years. His initial weight was 85&#x02009;Kg. He smoked 10 cigarettes per day. His psychosis started when he was 12 years old and had been refractory to treatment for many years at the time of admission. The patient had three seizures of unknown origin in the 3 months before coming under the care of the senior author. Academic neurologists had examined him at least twice. All tests, including a CT scan of the head, were negative. After a careful review of all records, it was the impression of the senior author that at least 1 or 2 of the 3 seizures might have been associated with rapid withdrawal of high doses of benzodiazepines, particularly temazepam, used as PRNs. He arrived at the unit with four antiepileptic medications in his regimen: carbamazepine, phenytoin, diazepam, and VPA. These medications had been progressively added by the neurology consultants. The blood levels of all four of these medications were subtherapeutic. After several months the senior author was able to change the regimen to VPA only, without the patient having any seizures during his long admission. The VPA treatment is described in detail in <xref ref-type="table" rid="tab2">Table 2</xref>. To avoid too much irrelevant information, day 164 of admission was selected as day 1 to describe the time-course of VPA treatment. The senior author was surprised that this patient needed 5250&#x02009;mg/day of VPA concentrate to get therapeutic VPA concentrations. After more than 3.5 years of admission, the patient was finally stabilized on clozapine at 700&#x02009;mg/day, his psychotic symptoms had greatly improved, and he was getting ready to be discharged. However, he then began to complain about the taste of the VPA concentrate in his mouth. With the assumption of bioequivalent formulations and dosing, the patient was switched to divalproex sodium at a total daily dose of 5250&#x02009;mg/day. This led to an unexpected VPA intoxication despite the absence of any other medication changes. This unexpected outcome left the senior author perplexed and led him to a brief preliminary publication on VPA concentrations during the last 3 months of admission [<xref rid="B33" ref-type="bibr">33</xref>], despite having no pharmacological explanation at that time. <xref ref-type="table" rid="tab2">Table 2</xref> presents a comprehensive list of the VPA concentrations during most of 4 years, as well as the corresponding VPA C/D ratios. While the patient was being maintained on 5250&#x02009;mg/day of VPA concentrate for many years, the VPA C/D ratio multiplied by 1000 yielded values ranging from 10 to 21 with a mean of 15. Divalproex sodium treatment yielded VPA C/D values which, multiplied by 1000, ranged from 28 to 48, with a mean of 39. The means of 19 and 39 were found to be significantly different (<xref ref-type="table" rid="tab2">Table 2</xref>, footnote 1), indicating that the patient's ability to metabolize VPA was significantly higher on VPA concentrate than on divalproex sodium.</p><p>It is likely that this case presentation reflects the result of VPA autoinduction only present during VPA concentrate versus no autoinduction during divalproex sodium use. The DIPS score was 6, which corresponds to a probable drug interaction in this case (scored as 1 point each for questions 2, 3, 4, 7, 8, and 9).</p></sec><sec id="sec3.2"><title>3.2. Case 2</title><p>Patient 2 was a 66-year-old Caucasian male nonsmoker with a 26-year history of bipolar disorder and a history of polysubstance abuse (alcohol and cocaine). His initial weight was 90&#x02009;Kg. He had 7 prior psychiatric admissions. On presentation the patient met the criteria for hypomanic episode with psychotic features. He had a positive viral panel for hepatitis C and his Hep C RNA PCR was positive, but his liver function profile and metabolic panel were unremarkable. Sublingual asenapine 20&#x02009;mg/day, one of his outpatient medications, was restarted by the third author on hospital day 2 in addition to VPA 1000&#x02009;mg/day, which the patient had not received as an outpatient. Other medications are described in <xref ref-type="table" rid="tab3">Table 3</xref>. The patient did not experience any signs of VPA toxicity as the dose was increased during his admission. However, he remained hypomanic and continued to display rapid, pressured speech and flight of ideas in addition to increased levels of energy. His VPA concentrations were monitored closely with gradual increases in his enterocoated divalproex sodium. Despite increasing his daily dose and switching to concentrate and then back to enterocoated divalproex sodium, the dose had to be progressively increased to a total of 4000&#x02009;mg/day to continue to have a therapeutic response and therapeutic levels. By the time of discharge, the patient's mood had become more euthymic. He was discharged after 10 weeks of inpatient management in stable condition and with a medication regimen including VPA at 4000&#x02009;mg/day. This patient was remarkable because, in order to maintain the therapeutic response and a VPA level around 70&#x02009;<italic>&#x003bc;</italic>g/mL, progressively higher doses from 1500 to 4000&#x02009;mg/day were needed to the point that the last VPA C/D ratio multiplied by 1000 had a value remarkably low (at 17) while being on a high dose of 4000&#x02009;mg/day and with a VPA concentration of only 67&#x02009;<italic>&#x003bc;</italic>g/mL. The mean C/D ratio multiplied by 1000 was 25 with a range from 17 to 33 (<xref ref-type="table" rid="tab3">Table 3</xref>). As a matter of fact, in spite of the limited number of VPA concentrations, there was a very strong correlation (<italic>r</italic> = 0.97; <italic>p</italic> &#x0003c; 0.001) between the number of days of admission and the dose, indicating that, with an increasing length of admission, the dose increased, and this high value remained after correcting for VPA concentrations using a partial correlation (<italic>r</italic> = 0.96; <italic>p</italic> &#x0003c; 0.001) (<xref ref-type="table" rid="tab3">Table 3</xref>, footnote 1). This is compatible with a progressive autoinduction; as the time after admission increased, it was necessary to increase the VPA dose. The patient was discharged on 4000&#x02009;mg/day; we do not know what happened after discharge, except that the patient had no relapses for 2 years after this admission.</p><p>Considering the need for higher doses to maintain the same VPA concentration, the DIPS score was 5 (scoring 1 point each for questions 2, 3, 4, 7, and 8), indicating a &#x0201c;probable&#x0201d; relationship between VPA and autoinduction activity.</p></sec><sec id="sec3.3"><title>3.3. Case 3</title><p>Patient 3 was a Caucasian male nonsmoker with a history of tuberous sclerosis, which manifested as seizure disorder and mental retardation. His initial weight was 71&#x02009;Kg. He had been an inpatient at a state psychiatric hospital for 22 years before the senior author started to manage his treatment (day 1) when the patient was 48 years old. Two years later he developed a right renal mass, which was highly suspicious for renal cell carcinoma on biopsy. It was followed by a right-sided nephrectomy and cholecystectomy (day 860). However, the final pathology suggested that the mass was actually angiomyolipoma, which is common if there is renal involvement in patients with tuberous sclerosis. Thorough investigation for left-sided pathology indicated that his left kidney was functioning well with stable masses present on CT. From day 1322, the patient progressively worsened with new-onset episodes of ataxia and confusion. High clinical suspicion for a brain mass led the senior author to investigate with MRI. The results indicated that the patient had a mass in the right lateral ventricle &#x0201c;suggestive of giant cell astrocytoma&#x0201d; and that &#x0201c;foci of enhancement at the gray-white junction and numerous signal abnormalities in the skull suggest the possibility of metastatic disease.&#x0201d; Giant cell astrocytomas occur in 6&#x02013;14% of patients with tuberous sclerosis and should be suspected when there is a new focal deficit, signs of increased intracranial pressure, or unexplained behavioral changes. After day 1420, when the brain tumor was diagnosed, we started trying to reduce the VPA dose and manage it on the basis of the patient's comfort rather than the VPA concentration level.</p><p>During the long follow-up of more than 4 years (almost 1500 days) described in <xref ref-type="table" rid="tab4">Table 4</xref>, the patient had therapeutic levels of phenytoin initially with 500&#x02009;mg/day and at the end with 400&#x02009;mg/day. VPA showed a completely different pattern, requiring a progressive increase in the dose to keep VPA therapeutic concentrations &#x0003e;50&#x02009;<italic>&#x003bc;</italic>g/mL. On day 1 the VPA dose was 3375&#x02009;mg/day, on day 400 it was 5000&#x02009;mg/day, on day 943 it was 9000&#x02009;mg/day, and on day 1029 it was 10500&#x02009;mg/day, which was maintained until it was clear that his physical deterioration was due to a brain tumor. At that time other medications were discontinued, only leaving phenytoin and a lower VPA dose (<xref ref-type="table" rid="tab4">Table 4</xref>).</p><p>Despite the necessity of increasing the VPA dose to this very high dosage, the phenytoin dose remained stable with normal blood levels in the therapeutic range. This suggests that the progressive increase in VPA metabolism was not associated with an increase in phenytoin metabolism. The VPA C/D ratios in this patient were extremely low, frequently lower than 10. The mean C/D ratio multiplied by 1000 for 70 therapeutic concentrations was 8 with a range from 5 to 18 (<xref ref-type="table" rid="tab3">Table 3</xref>). As a matter of fact, there was a very strong correlation (<italic>r</italic> = 0.97; <italic>p</italic> &#x0003c; 0.001) between the number of days past admission and the dose, indicating that with an increasing length of admission, the dose increased, and this significance remained after correcting for VPA concentrations using a partial correlation (<italic>r</italic> = 0.89; <italic>p</italic> &#x0003c; 0.001) (<xref ref-type="table" rid="tab4">Table 4</xref>, footnote 1). This is compatible with a progressive autoinduction.</p><p>Using the DIPS as in the previous cases, the total score was 5 (scoring 1 point each for questions 2, 3, 4, 7, and 8), indicating a &#x0201c;probable&#x0201d; relationship between VPA and the autoinduction of its metabolism.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><sec id="sec4.1"><title>4.1. Limitations</title><p>These 3 cases reflect 3 extremely challenging patients who required very high doses of VPA &#x0003e;4000&#x02009;mg/day to maintain VPA therapeutic levels. As usual in these challenging cases, the pharmacological data is somewhat limited since patients were treated with polypharmacy and went through complex changes in medications. In spite of the data limitations, we think that these cases need to be published to acknowledge that while these patients are very rare, they exist. In support of the above findings, however, the senior author was closely involved in the treatment of the 3 patients and all VPA concentrations were measured in the same lab. It is rare to see publications describe so many large measures of VPA concentrations.</p><p>The data is limited but undeniable and should indicate to any clinician that these 3 patients needed daily doses of VPA to get therapeutic VPA concentrations. The second and greater limitation in analyzing these cases is our interpretation of the data many years after they were collected&#x02014;in the third case, almost 20 years. It has required that much time to accumulate evidence in the literature to understand what happened and to realize that VPA may be an inducer; in fact, it can induce its own metabolism. Therefore, although these VPA concentrations were collected prospectively and used to modify VPA doses, they were reviewed retrospectively to provide the unified hypothesis that it is possible that these high VPA doses were required because these 3 patients were unusually sensitive to VPA autoinduction. In retrospect, after having a possible pharmacological explanation now after many years, it would have been better to collect more frequent TDM data, but what is described is what is available. Although we acknowledge that the data is limited and our interpretation is even more limited, we have tried to support our interpretation through the use of statistical tests and a validated scale.</p></sec><sec id="sec4.2"><title>4.2. High Doses of VPA May Be Explained by VPA Autoinduction</title><p>We think these cases contribute to the scarce literature by indicating that clinicians must be aware that VPA may behave as an inducer. In Cases 1 and 3, patients with likely VPA autoinduction presented significant clinical challenges to the senior author, who had no idea why the patients required much higher VPA dosages to obtain therapeutic VPA concentrations. Case 2 was identified only 4 years ago when the senior author realized that VPA autoinduction was clinically relevant for some peculiar patients. As a matter of fact, Case 2 was identified by the third author, who had rarely seen similar cases. The senior author suggested to her that these cases were probably explained by autoinduction and she was able to identify this patient as a candidate for VPA autoinduction shortly after admission.</p><p>The first patient was very challenging, probably the most challenging patient in the senior author's career, even with his more than 25-year history of treating treatment-refractory patients. The patient metabolized the CYP1A2 drugs clozapine and olanzapine normally but got intoxicated on clozapine during an infection [<xref rid="B34" ref-type="bibr">34</xref>]. He appeared unusual because he needed 5250&#x02009;mg/day of VPA concentrate for several years to get therapeutic VPA concentrations. The senior author had experience in switching many patients back and forth from VPA concentrate to divalproex sodium using the same doses and getting similar VPA concentrations. In fact, the US prescribing information from the drug manufacturer recommended and continues to recommend initiating the same total daily doses when converting a patient from VPA to divalproex sodium. A published study reported a statistically significant decrease of 14.4% (<italic>p</italic> = 0.001) in VPA plasma concentrations upon switching dosage forms from divalproex sodium to VPA [<xref rid="B35" ref-type="bibr">35</xref>]. Therefore, the senior author expected a minor increase of around 14.4% in switching from 5250&#x02009;mg/day of VPA concentrate but, instead, he intoxicated the patient. The VPA concentration went from the 80s&#x02009;<italic>&#x003bc;</italic>g/mL to 145&#x02009;<italic>&#x003bc;</italic>g/mL and required halving the dose to 2000&#x02009;mg/day of divalproex sodium to get VPA concentrations in the 80s&#x02009;<italic>&#x003bc;</italic>g/mL. In retrospect, during treatment with VPA concentrate, the VPA C/D ratio multiplied by 1000 was extremely low, at a mean of 15 and a range of 10&#x02013;21, indicating an extraordinarily high capacity to metabolize VPA. This is compatible with VPA concentrate inducing its own metabolism. We propose that after 4 weeks on divalproex sodium the autoinduction was lost and the patient's metabolism normalized, with a mean VPA C/D ratio multiplied by 1000 of 39 and a range of 28 to 48. We cannot explain why this patient's VPA concentrate appeared to induce its own metabolism while divalproex sodium did not; we assume this patient had some rare genetic variation that explains his peculiar response.</p><p>The second patient had a relatively short admission (&#x0003c;60 days) but demonstrated a very high and significant correlation between length of admission and VPA dose. The final C/D ratio was 17, extremely low. This type of patient is probably more common than Case 1; his treating psychiatrist, the third author, has seen several similar cases in her 25-year practice in patients with severe mental illness including 20 years at this psychiatric hospital.</p><p>The third patient probably deserved a Guinness record since he was treated with 10500&#x02009;mg/day for 400 days and had a VPA C/D ratio multiplied by 1000 which yielded a value less than 10 most of the time. We have the impression that progressive VPA autoinduction explained the need to go from 3450 to 10500&#x02009;mg/day to achieve and maintain VPA concentrations &#x0003e;50&#x02009;<italic>&#x003bc;</italic>g/mL. It is possible that phenytoin treatment contributed in some way to the facilitation of VPA autoinduction, since phenytoin is a major inducer and can displace VPA from plasmatic proteins. It is remarkable that although increases in VPA dosage were needed to get therapeutic VPA concentrations, the phenytoin dosage needed to obtain therapeutic phenytoin concentrations was relatively stable throughout this time period. Phenytoin doses ranged from 500&#x02009;mg/day at the beginning to 400&#x02009;mg/day at the end. This minor reduction in dosage may be explained by the greater VPA concentrations at the end. VPA is an inhibitor of phenytoin metabolism. Unfortunately, 20 years ago, free VPA and phenytoin concentrations were not available at this psychiatric hospital. It would have been important to measure them [<xref rid="B29" ref-type="bibr">29</xref>].</p></sec><sec id="sec4.3"><title>4.3. The Pharmacological Mechanism behind VPA Induction</title><p>The induction of metabolic enzymes such as UGTs implies that the amount of these proteins increases when they are induced; this is almost always explained by increasing protein synthesis mediated by the so-called nuclear receptors (constitutive androstane, estrogen, glucocorticoid receptors, and pregnane X receptors) or other transcription factors such as aryl hydrocarbon receptors. The potent AED inducers (carbamazepine, phenytoin, and phenobarbital) bind to the pregnane X receptors. Phenytoin and phenobarbital appear to also bind to the constitutive androstane receptors. VPA is a less potent inducer but probably works in a similar way. An in vitro study suggested that VPA might also activate constitutive androstane receptor and pregnane X receptor pathways [<xref rid="B14" ref-type="bibr">14</xref>].</p><p>We think it is possible that these unusual patients needing very high VPA dosages have unusual genetic variants at the nuclear receptors, which made them very sensitive to VPA autoinduction.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge Lorraine Maw, M. A., who helped in editing this paper, and Kay Marshall, who was at that time Lab Director at the Psychiatric Hospital, and her staff were very helpful with the collection and analyses of the blood samples during all of these years.</p></ack><sec><title>Disclaimer</title><p>No commercial organizations had any role in the writing of this paper for publication.</p></sec><sec sec-type="conflict"><title>Conflict of Interests</title><p>In the last 3 years, the authors had no conflict of interests.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>G. M.</given-names></name><name><surname>Naunton</surname><given-names>M.</given-names></name></person-group><article-title>Valproate: a simple chemical with so much to offer</article-title><source><italic>Journal of Clinical Pharmacy and Therapeutics</italic></source><year>2005</year><volume>30</volume><issue>5</issue><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2005.00671.x</pub-id><pub-id pub-id-type="other">2-s2.0-27744487691</pub-id><pub-id pub-id-type="pmid">16164485</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="book"><collab>Lexicomp</collab><source><italic>Drug Information Handbook</italic></source><year>2014</year><edition>23rd</edition><publisher-loc>Hudson, Ohio, USA</publisher-loc><publisher-name>Lexi-Comp</publisher-name></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patsalos</surname><given-names>P. N.</given-names></name><name><surname>Berry</surname><given-names>D. J.</given-names></name><name><surname>Bourgeois</surname><given-names>B. F. D.</given-names></name><etal/></person-group><article-title>Antiepileptic drugs&#x02014;best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies</article-title><source><italic>Epilepsia</italic></source><year>2008</year><volume>49</volume><issue>7</issue><fpage>1239</fpage><lpage>1276</lpage><pub-id pub-id-type="other">2-s2.0-45749150011</pub-id><pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01561.x</pub-id><pub-id pub-id-type="pmid">18397299</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>G. D.</given-names></name></person-group><article-title>A mechanistic approach to antiepileptic drug interactions</article-title><source><italic>Annals of Pharmacotherapy</italic></source><year>1998</year><volume>32</volume><issue>5</issue><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1345/aph.17332</pub-id><pub-id pub-id-type="other">2-s2.0-0031800865</pub-id><pub-id pub-id-type="pmid">9606477</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeVane</surname><given-names>C. L.</given-names></name></person-group><article-title>Pharmacokinetics, drug interactions, and tolerability of valproate</article-title><source><italic>Psychopharmacology Bulletin</italic></source><year>2003</year><volume>37</volume><issue>supplement 2</issue><fpage>25</fpage><lpage>42</lpage><pub-id pub-id-type="other">2-s2.0-3242690866</pub-id><pub-id pub-id-type="pmid">14624231</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>J.</given-names></name><name><surname>Chetty</surname><given-names>M.</given-names></name></person-group><article-title>Psychotropic drug interactions with valproate</article-title><source><italic>Clinical Neuropharmacology</italic></source><year>2005</year><volume>28</volume><issue>2</issue><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1097/01.wnf.0000154221.37887.73</pub-id><pub-id pub-id-type="other">2-s2.0-16344384706</pub-id><pub-id pub-id-type="pmid">15795555</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiang</surname><given-names>T. K. L.</given-names></name><name><surname>Ho</surname><given-names>P. C.</given-names></name><name><surname>Anari</surname><given-names>M. R.</given-names></name><name><surname>Tong</surname><given-names>V.</given-names></name><name><surname>Abbott</surname><given-names>F. S.</given-names></name><name><surname>Chang</surname><given-names>T. K. H.</given-names></name></person-group><article-title>Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9<sup>*</sup>1/<sup>*</sup>1 genotype</article-title><source><italic>Toxicological Sciences</italic></source><year>2006</year><volume>94</volume><issue>2</issue><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfl096</pub-id><pub-id pub-id-type="other">2-s2.0-33751423375</pub-id><pub-id pub-id-type="pmid">16945988</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>G.</given-names></name><name><surname>Ono</surname><given-names>S.</given-names></name><name><surname>Yasui-Furukori</surname><given-names>N.</given-names></name><name><surname>Nakamura</surname><given-names>A.</given-names></name><name><surname>Mihara</surname><given-names>K.</given-names></name><name><surname>Kondo</surname><given-names>T.</given-names></name></person-group><article-title>Formulations of valproate alter valproate metabolism: a single oral dose kinetic study</article-title><source><italic>Therapeutic Drug Monitoring</italic></source><year>2009</year><volume>31</volume><issue>5</issue><fpage>592</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1097/ftd.0b013e3181b777f9</pub-id><pub-id pub-id-type="other">2-s2.0-70349653062</pub-id><pub-id pub-id-type="pmid">19704403</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argikar</surname><given-names>U. A.</given-names></name><name><surname>Remmel</surname><given-names>R. P.</given-names></name></person-group><article-title>Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10</article-title><source><italic>Drug Metabolism and Disposition</italic></source><year>2009</year><volume>37</volume><issue>1</issue><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1124/dmd.108.022426</pub-id><pub-id pub-id-type="other">2-s2.0-58149469245</pub-id><pub-id pub-id-type="pmid">18838507</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>J. E.</given-names></name><name><surname>Nau</surname><given-names>H.</given-names></name><name><surname>L&#x000f6;scher</surname><given-names>W.</given-names></name></person-group><article-title>Alterations in the renal excretion of valproate and its metabolites after chronic treatment</article-title><source><italic>Epilepsia</italic></source><year>1991</year><volume>32</volume><issue>1</issue><fpage>146</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1991.tb05627.x</pub-id><pub-id pub-id-type="other">2-s2.0-0025967232</pub-id><pub-id pub-id-type="pmid">1985825</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooper</surname><given-names>W. D.</given-names></name><name><surname>Franklin</surname><given-names>M. E.</given-names></name><name><surname>Glue</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Effect of felbamate on valproic acid disposition in healthy volunteers: Inhibition of beta-oxidation</article-title><source><italic>Epilepsia</italic></source><year>1996</year><volume>37</volume><issue>1</issue><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1996.tb00518.x</pub-id><pub-id pub-id-type="other">2-s2.0-0030048917</pub-id><pub-id pub-id-type="pmid">8603632</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>G. D.</given-names></name><name><surname>Yau</surname><given-names>M. K.</given-names></name><name><surname>Gidal</surname><given-names>B. E.</given-names></name><etal/></person-group><article-title>Bidirectional interaction of valproate and lamotrigine in healthy subjects</article-title><source><italic>Clinical Pharmacology &#x00026; Therapeutics</italic></source><year>1996</year><volume>60</volume><issue>2</issue><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/s0009-9236(96)90130-7</pub-id><pub-id pub-id-type="other">2-s2.0-0029909431</pub-id><pub-id pub-id-type="pmid">8823232</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>D. B.</given-names></name><name><surname>Andrews</surname><given-names>J. A.</given-names></name><name><surname>Hooper</surname><given-names>W. D.</given-names></name><name><surname>Canned</surname><given-names>G. R.</given-names></name><name><surname>Eadie</surname><given-names>M. J.</given-names></name><name><surname>Dickinson</surname><given-names>R. G.</given-names></name></person-group><article-title>Apparent autoinduction of valproate <italic>&#x003b2;</italic>-oxidation in humans</article-title><source><italic>British Journal of Clinical Pharmacology</italic></source><year>2000</year><volume>49</volume><issue>5</issue><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2000.00191.x</pub-id><pub-id pub-id-type="other">2-s2.0-0034107794</pub-id><pub-id pub-id-type="pmid">10792197</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerveny</surname><given-names>L.</given-names></name><name><surname>Svecova</surname><given-names>L.</given-names></name><name><surname>Anzenbacherova</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways</article-title><source><italic>Drug Metabolism and Disposition</italic></source><year>2007</year><volume>35</volume><issue>7</issue><fpage>1032</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1124/dmd.106.014456</pub-id><pub-id pub-id-type="other">2-s2.0-34250758597</pub-id><pub-id pub-id-type="pmid">17392393</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>F. A.</given-names></name><name><surname>van der Bol</surname><given-names>J. M.</given-names></name><name><surname>Mathijssen</surname><given-names>R. H. J.</given-names></name><etal/></person-group><article-title>Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity</article-title><source><italic>Cancer Biology &#x00026; Therapy</italic></source><year>2007</year><volume>6</volume><issue>9</issue><fpage>1368</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.mct-05-0414</pub-id><pub-id pub-id-type="other">2-s2.0-42549109974</pub-id><pub-id pub-id-type="pmid">17873515</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Citrome</surname><given-names>L.</given-names></name><name><surname>Josiassen</surname><given-names>R.</given-names></name><name><surname>Bark</surname><given-names>N.</given-names></name><name><surname>Salazar</surname><given-names>D. E.</given-names></name><name><surname>Mallikaarjun</surname><given-names>S.</given-names></name></person-group><article-title>Pharmacokinetics of aripiprazole and concomitant lithium and valproate</article-title><source><italic>Journal of Clinical Pharmacology</italic></source><year>2005</year><volume>45</volume><issue>1</issue><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1177/0091270004269870</pub-id><pub-id pub-id-type="other">2-s2.0-16644393062</pub-id><pub-id pub-id-type="pmid">15601809</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergemann</surname><given-names>N.</given-names></name><name><surname>Kress</surname><given-names>K. R.</given-names></name><name><surname>Abu-Tair</surname><given-names>F.</given-names></name><name><surname>Frick</surname><given-names>A.</given-names></name><name><surname>Kopitz</surname><given-names>J.</given-names></name></person-group><article-title>Valproate lowers plasma concentration of olanzapine</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2006</year><volume>26</volume><issue>4</issue><fpage>432</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1097/01.jcp.0000227353.46450.52</pub-id><pub-id pub-id-type="other">2-s2.0-33746880605</pub-id><pub-id pub-id-type="pmid">16855466</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haslemo</surname><given-names>T.</given-names></name><name><surname>Olsen</surname><given-names>K.</given-names></name><name><surname>Lunde</surname><given-names>H.</given-names></name><name><surname>Molden</surname><given-names>E.</given-names></name></person-group><article-title>Valproic acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking</article-title><source><italic>Therapeutic Drug Monitoring</italic></source><year>2012</year><volume>34</volume><issue>5</issue><fpage>512</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e3182693d2a</pub-id><pub-id pub-id-type="other">2-s2.0-84866530124</pub-id><pub-id pub-id-type="pmid">22972535</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botts</surname><given-names>S.</given-names></name><name><surname>Diaz</surname><given-names>F. J.</given-names></name><name><surname>Santoro</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model</article-title><source><italic>Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic></source><year>2008</year><volume>32</volume><issue>6</issue><fpage>1453</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.04.018</pub-id><pub-id pub-id-type="other">2-s2.0-47749087003</pub-id><pub-id pub-id-type="pmid">18555573</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spina</surname><given-names>E.</given-names></name><name><surname>D'Arrigo</surname><given-names>C.</given-names></name><name><surname>Santoro</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder</article-title><source><italic>Therapeutic Drug Monitoring</italic></source><year>2009</year><volume>31</volume><issue>6</issue><fpage>758</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e3181c0590e</pub-id><pub-id pub-id-type="other">2-s2.0-73849131328</pub-id><pub-id pub-id-type="pmid">19865002</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finley</surname><given-names>P.</given-names></name><name><surname>Warner</surname><given-names>D.</given-names></name></person-group><article-title>Potential impact of valproic acid therapy on clozapine disposition</article-title><source><italic>Biological Psychiatry</italic></source><year>1994</year><volume>36</volume><issue>7</issue><fpage>487</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/0006-3223(94)90647-5</pub-id><pub-id pub-id-type="other">2-s2.0-0028146698</pub-id><pub-id pub-id-type="pmid">7811848</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname><given-names>L. P.</given-names></name><name><surname>Salzman</surname><given-names>C.</given-names></name></person-group><article-title>Valproic acid effects on serum concentrations of clozapine and norclozapine</article-title><source><italic>The American Journal of Psychiatry</italic></source><year>1995</year><volume>152</volume><issue>4</issue><fpage>p. 650</fpage><pub-id pub-id-type="other">2-s2.0-0028917675</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riesselman</surname><given-names>A.</given-names></name><name><surname>Strobl</surname><given-names>B.</given-names></name><name><surname>Cooley</surname><given-names>A. T.</given-names></name><name><surname>de Leon</surname><given-names>J.</given-names></name></person-group><article-title>A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2013</year><volume>33</volume><issue>6</issue><fpage>812</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1097/jcp.0b013e3182a4ea8f</pub-id><pub-id pub-id-type="other">2-s2.0-84888137126</pub-id><pub-id pub-id-type="pmid">24113673</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>F. J.</given-names></name><name><surname>Santoro</surname><given-names>V.</given-names></name><name><surname>Spina</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables</article-title><source><italic>Pharmacopsychiatry</italic></source><year>2008</year><volume>41</volume><issue>3</issue><fpage>81</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1055/s-2007-1004591</pub-id><pub-id pub-id-type="other">2-s2.0-44849135619</pub-id><pub-id pub-id-type="pmid">18484549</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>F. J.</given-names></name><name><surname>Eap</surname><given-names>C. B.</given-names></name><name><surname>Ansermot</surname><given-names>N.</given-names></name><name><surname>Crettol</surname><given-names>S.</given-names></name><name><surname>Spina</surname><given-names>E.</given-names></name><name><surname>De Leon</surname><given-names>J.</given-names></name></person-group><article-title>Can valproic acid be an inducer of clozapine metabolism?</article-title><source><italic>Pharmacopsychiatry</italic></source><year>2014</year><volume>47</volume><issue>3</issue><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1371866</pub-id><pub-id pub-id-type="other">2-s2.0-84901341793</pub-id><pub-id pub-id-type="pmid">24764199</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrzal</surname><given-names>R.</given-names></name><name><surname>Doricakova</surname><given-names>A.</given-names></name><name><surname>Novotna</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: a possible cause of valproic acid-induced osteomalacia?</article-title><source><italic>Toxicology Letters</italic></source><year>2011</year><volume>200</volume><issue>3</issue><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2010.11.008</pub-id><pub-id pub-id-type="other">2-s2.0-78651100063</pub-id><pub-id pub-id-type="pmid">21115105</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leon</surname><given-names>J.</given-names></name><name><surname>Spina</surname><given-names>E.</given-names></name><name><surname>Diaz</surname><given-names>F. J.</given-names></name></person-group><article-title>Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies</article-title><source><italic>Therapeutic Drug Monitoring</italic></source><year>2013</year><volume>35</volume><issue>1</issue><fpage>30</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1097/ftd.0b013e31827ada88</pub-id><pub-id pub-id-type="other">2-s2.0-84872845726</pub-id><pub-id pub-id-type="pmid">23318278</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spina</surname><given-names>E.</given-names></name><name><surname>de Leon</surname><given-names>J.</given-names></name></person-group><article-title>Clinical applications of CYP genotyping in psychiatry</article-title><source><italic>Journal of Neural Transmission</italic></source><year>2015</year><volume>122</volume><issue>1</issue><fpage>5</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1007/s00702-014-1300-5</pub-id><pub-id pub-id-type="pmid">25200585</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leon</surname><given-names>J.</given-names></name><name><surname>Kiesel</surname><given-names>J. L.</given-names></name><name><surname>Fleming</surname><given-names>M. W.</given-names></name><name><surname>Strobl</surname><given-names>B.</given-names></name></person-group><article-title>Valproic acid toxicity associated with low dose of aspirin and low total valproic acid levels: a case report</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2009</year><volume>29</volume><issue>5</issue><fpage>509</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1097/jcp.0b013e3181b4b07c</pub-id><pub-id pub-id-type="other">2-s2.0-70349656040</pub-id><pub-id pub-id-type="pmid">19745660</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-P&#x000e9;rez</surname><given-names>R.</given-names></name><name><surname>&#x000c1;lvarez-Doba&#x000f1;o</surname><given-names>J. M.</given-names></name><name><surname>Su&#x000e1;rez-Antelo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Eosinophilic pleural effusion associated with the addition of sodium valproate</article-title><source><italic>Journal of Clinical Psychopharmacology</italic></source><year>2009</year><volume>29</volume><issue>3</issue><fpage>310</fpage><lpage>311</lpage><pub-id pub-id-type="other">2-s2.0-67649243655</pub-id><pub-id pub-id-type="doi">10.1097/JCP.0b013e3181a2e1cf</pub-id><pub-id pub-id-type="pmid">19440094</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>K. T.</given-names></name><name><surname>Sonne</surname><given-names>S. C.</given-names></name><name><surname>Anton</surname><given-names>R.</given-names></name><name><surname>Ballenger</surname><given-names>J. C.</given-names></name></person-group><article-title>Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study</article-title><source><italic>Journal of Clinical Psychiatry</italic></source><year>1995</year><volume>56</volume><issue>3</issue><fpage>118</fpage><lpage>121</lpage><pub-id pub-id-type="other">2-s2.0-0028948046</pub-id><pub-id pub-id-type="pmid">7883730</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>J. R.</given-names></name><name><surname>Hansten</surname><given-names>P. D.</given-names></name><name><surname>Chan</surname><given-names>L. N.</given-names></name></person-group><article-title>Proposal for a new tool to evaluate drug interaction cases</article-title><source><italic>Annals of Pharmacotherapy</italic></source><year>2007</year><volume>41</volume><issue>4</issue><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="other">2-s2.0-34247231457</pub-id><pub-id pub-id-type="doi">10.1345/aph.1h423</pub-id><pub-id pub-id-type="pmid">17389673</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>G.</given-names></name><name><surname>Botts</surname><given-names>S.</given-names></name><name><surname>de Leon</surname><given-names>J.</given-names></name></person-group><article-title>Dosing differences between valproic acid concentrate and divalproex sodium: a case report</article-title><source><italic>The Journal of Clinical Psychiatry</italic></source><year>2004</year><volume>65</volume><issue>5</issue><fpage>724</fpage><lpage>725</lpage><pub-id pub-id-type="other">2-s2.0-2942724323</pub-id><pub-id pub-id-type="pmid">15163266</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leon</surname><given-names>J.</given-names></name><name><surname>Diaz</surname><given-names>F. J.</given-names></name></person-group><article-title>Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report</article-title><source><italic>Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic></source><year>2003</year><volume>27</volume><issue>6</issue><fpage>1059</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1016/s0278-5846(03)00148-9</pub-id><pub-id pub-id-type="other">2-s2.0-0141851847</pub-id><pub-id pub-id-type="pmid">14499324</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>J. D.</given-names></name><name><surname>Kelly</surname><given-names>D. L.</given-names></name></person-group><article-title>Substitution of immediate-release valproic acid for divalproex sodium for adult psychiatric inpatients</article-title><source><italic>Psychiatric Services</italic></source><year>1998</year><volume>49</volume><issue>10</issue><fpage>1355</fpage><lpage>1357</lpage><pub-id pub-id-type="other">2-s2.0-0031665435</pub-id><pub-id pub-id-type="doi">10.1176/ps.49.10.1355</pub-id><pub-id pub-id-type="pmid">9779912</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Explaining VPA C/D ratio use with VPA concentrations from a published case [<xref rid="B29" ref-type="bibr">29</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Formulation</th><th align="center" rowspan="1" colspan="1">VPA dose (mg/day)</th><th align="center" rowspan="1" colspan="1">Concentration (<italic>&#x003bc;</italic>g/mL)</th><th align="center" rowspan="1" colspan="1">C/D ratio</th><th align="center" rowspan="1" colspan="1">C/D ratio &#x000d7; 1000</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">0.112</td><td align="center" rowspan="1" colspan="1">112</td></tr><tr><td align="left" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">750</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0.116</td><td align="center" rowspan="1" colspan="1">116</td></tr><tr><td align="left" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">0.132</td><td align="center" rowspan="1" colspan="1">132</td></tr><tr><td align="left" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">0.128</td><td align="center" rowspan="1" colspan="1">128</td></tr></tbody></table><table-wrap-foot><fn><p>C/D: concentration-to-dose; ECDVNa: divalproex sodium enterocoated; VPA: valproic acid.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>VPA C/D ratio in Case 1.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Day</th><th align="center" rowspan="1" colspan="1">VPA dose (mg/day)</th><th align="center" rowspan="1" colspan="1">Concentration (<italic>&#x003bc;</italic>g/mL)</th><th align="center" rowspan="1" colspan="1">C/D ratio</th><th align="center" rowspan="1" colspan="1">C/D ratio &#x000d7; 1000</th></tr></thead><tbody><tr><td align="center" colspan="5" rowspan="1">Valproic acid concentrate (C/D ratio &#x000d7; 1000: mean &#x000b1; SD = 15<sup>1</sup>&#x02009;&#x02009;&#x000b1; 2.6, range = 10&#x02013;21)</td></tr><tr><td align="left" rowspan="1" colspan="1">7<sup>3</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">14<sup>4</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">21<sup>5</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">29<sup>5</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">70<sup>5</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">98<sup>6</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">119<sup>6</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">126<sup>6</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">140<sup>6</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">175<sup>6</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">188<sup>6</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">202<sup>7</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">238<sup>8</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">252<sup>8</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">0.021</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">260<sup>9</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">280<sup>9</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">287<sup>9</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">301<sup>10</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">319<sup>10</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">350<sup>10</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">0.019</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">378<sup>11</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">420<sup>12</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">427<sup>12</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">434<sup>12</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">470<sup>12</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">498<sup>13</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">552<sup>13</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">582<sup>13</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">609<sup>13</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">637<sup>7</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">928<sup>14</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">0.021</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">945<sup>15</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">978<sup>16</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">998<sup>17</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1026<sup>18</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1054<sup>19</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1082<sup>19</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">1110<sup>19</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">1145<sup>20</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1166<sup>21</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">93</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">1202<sup>22</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">1208<sup>23</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">1236<sup>24</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">1251<sup>25</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="center" colspan="5" rowspan="1">EC divalproex sodium (C/D ratio &#x000d7; 1000: mean &#x000b1; SD = 39<sup>1</sup>&#x02009;&#x02009;&#x000b1; 6.3, range = 28&#x02013;48)</td></tr><tr><td align="left" rowspan="1" colspan="1">1306<sup>25</sup></td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">145<sup>2</sup></td><td align="center" rowspan="1" colspan="1">0.028</td><td align="center" rowspan="1" colspan="1">28</td></tr><tr><td align="left" rowspan="1" colspan="1">1320<sup>25</sup></td><td align="center" rowspan="1" colspan="1">3750</td><td align="center" rowspan="1" colspan="1">135</td><td align="center" rowspan="1" colspan="1">0.036</td><td align="center" rowspan="1" colspan="1">36</td></tr><tr><td align="left" rowspan="1" colspan="1">1334<sup>25</sup></td><td align="center" rowspan="1" colspan="1">3000</td><td align="center" rowspan="1" colspan="1">127</td><td align="center" rowspan="1" colspan="1">0.042</td><td align="center" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="1" colspan="1">1373<sup>25</sup></td><td align="center" rowspan="1" colspan="1">2500</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">0.048</td><td align="center" rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1">1348<sup>25</sup></td><td align="center" rowspan="1" colspan="1">2000</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">0.037</td><td align="center" rowspan="1" colspan="1">37</td></tr><tr><td align="left" rowspan="1" colspan="1">1362<sup>25</sup></td><td align="center" rowspan="1" colspan="1">2000</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">0.041</td><td align="center" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">1376<sup>25</sup></td><td align="center" rowspan="1" colspan="1">2000</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">0.039</td><td align="center" rowspan="1" colspan="1">39</td></tr></tbody></table><table-wrap-foot><fn><p>C/D: concentration-to-dose; EC: enterocoated; VPA: valproic acid.</p></fn><fn><p>
<sup>1</sup>According to an independent <italic>t</italic>-test calculated with equal variance not assumed, there was significant difference (<italic>t</italic> = &#x02212;9.6; df = 6.3, <italic>p</italic> &#x0003c; 0.001) between these two means, 15 in VPA concentrate and 39 in divalproex sodium. </p></fn><fn><p>
<sup>2</sup>This VPA concentration was measured 4 weeks after switching from VPA concentrate to divalproex sodium. With a high VPA concentration at that time, the patient showed increased drowsiness. </p></fn><fn><p>
<sup>3</sup>Other scheduled oral medications included benztropine 3&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, propranolol 80&#x02009;mg/day, and quetiapine 700&#x02009;mg/day.</p></fn><fn><p>
<sup>4</sup>Other scheduled oral medications included benztropine 3&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 5&#x02009;mg/day, propranolol 80&#x02009;mg/day, and quetiapine 500&#x02009;mg/day.</p></fn><fn><p>
<sup>5</sup>Other scheduled oral medications included benztropine 3&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 5&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>6</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 5&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>7</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 5&#x02009;mg/day, and propranolol 60&#x02009;mg/day.</p></fn><fn><p>
<sup>8</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 2.5&#x02009;mg/day, and propranolol 30&#x02009;mg/day.</p></fn><fn><p>
<sup>9</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 2.5&#x02009;mg/day, and propranolol 40&#x02009;mg/day.</p></fn><fn><p>
<sup>10</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 2.5&#x02009;mg/day, and propranolol 60&#x02009;mg/day.</p></fn><fn><p>
<sup>11</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 2.5&#x02009;mg/day, and propranolol 120&#x02009;mg/day.</p></fn><fn><p>
<sup>12</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, clonidine 0.1&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 2.5&#x02009;mg/day, and propranolol 60&#x02009;mg/day.</p></fn><fn><p>
<sup>13</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 2.5&#x02009;mg/day, and propranolol 60&#x02009;mg/day.</p></fn><fn><p>
<sup>14</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, clozapine 25&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 10&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>15</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, clozapine 300&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 10&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>16</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, clozapine 600&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 10&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>17</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, clozapine 400&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 10&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>18</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, clozapine 700&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, olanzapine 10&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>19</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, clozapine 800&#x02009;mg/day, gemfibrozil 1200&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>20</sup>Other scheduled oral medications included atorvastatin 10&#x02009;mg/day, benztropine 4&#x02009;mg/day, clozapine 800&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>21</sup>Other scheduled oral medications included atorvastatin 20&#x02009;mg/day, benztropine 4&#x02009;mg/day, clozapine 800&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>22</sup>Other scheduled oral medications included atorvastatin 20&#x02009;mg/day, clozapine 700&#x02009;mg/day, docusate 250&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>23</sup>Other scheduled oral medications included atorvastatin 20&#x02009;mg/day, benztropine 0.5&#x02009;mg/day, clozapine 700&#x02009;mg/day, docusate 250&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>24</sup>Other scheduled oral medications included atorvastatin 20&#x02009;mg/day, benztropine 1&#x02009;mg/day, clozapine 600&#x02009;mg/day, docusate 250&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn><fn><p>
<sup>25</sup>Other scheduled oral medications included atorvastatin 20&#x02009;mg/day, benztropine 1&#x02009;mg/day, clozapine 700&#x02009;mg/day, docusate 250&#x02009;mg/day, and propranolol 80&#x02009;mg/day.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>VPA C/D ratio in Case 2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Day<sup>1</sup></th><th align="center" rowspan="1" colspan="1">Formulation</th><th align="center" rowspan="1" colspan="1">VPA dose<sup>1</sup> (mg/day)</th><th align="center" rowspan="1" colspan="1">Concentration (<italic>&#x003bc;</italic>g/mL)</th><th align="center" rowspan="1" colspan="1">C/D ratio</th><th align="center" rowspan="1" colspan="1">C/D ratio &#x000d7; 1000<sup>2</sup></th></tr></thead><tbody><tr><td align="center" colspan="6" rowspan="1">All 10 VPA concentrations (C/D ratio &#x000d7; 1000: mean &#x000b1; SD = 25 &#x000b1; 5.6, range = 17&#x02013;33)</td></tr><tr><td align="center" colspan="6" rowspan="1">8 therapeutic<sup>2</sup> VPA concentrations (C/D ratio &#x000d7; 1000: mean &#x000b1; SD = 24 &#x000b1; 5.6, range = 17&#x02013;33)</td></tr><tr><td align="left" rowspan="1" colspan="1">5<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">1500</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">0.026</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">8<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">1500</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">0.033 </td><td align="center" rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">14<sup>4</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">2500</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">0.024 </td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">20<sup>5</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">2500</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">0.030 </td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">23<sup>6</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">2500</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">0.033 </td><td align="center" rowspan="1" colspan="1">33</td></tr><tr><td align="left" rowspan="1" colspan="1">29<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3000</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">0.026 </td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">36<sup>7</sup></td><td align="center" rowspan="1" colspan="1">Concentrate</td><td align="center" rowspan="1" colspan="1">3500</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">0.020</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">41<sup>7</sup></td><td align="center" rowspan="1" colspan="1">Concentrate </td><td align="center" rowspan="1" colspan="1">3500</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">0.022 </td><td align="center" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">48<sup>8</sup></td><td align="center" rowspan="1" colspan="1">Concentrate </td><td align="center" rowspan="1" colspan="1">4000</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">0.018 </td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">55<sup>9</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4000</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">0.017 </td><td align="center" rowspan="1" colspan="1">17</td></tr></tbody></table><table-wrap-foot><fn><p>C/D: concentration-to-dose; ECDVNa: enterocoated divalproex sodium; VPA: valproic acid.</p></fn><fn><p>
<sup>1</sup>The Pearson correlation between day of admission and VPA dose was <italic>r</italic> = 0.97 (<italic>p</italic> &#x0003c; 0.001); VPA dose remained significant in a partial correlation while controlling for VPA concentration: <italic>r</italic> = 0.96 (<italic>p</italic> &#x0003c; 0.001). This is compatible with a progressive autoinduction indicating, at least with dose range, that it was necessary to increase the dose as the duration lengthened.</p></fn><fn><p>
<sup>2</sup>50&#x02013;125&#x02009;<italic>&#x003bc;</italic>g/mL concentrations are considered therapeutic concentrations. As this patient has 2 nontherapeutic concentrations, it would be better to compare a priori with other patients using only the VPA therapeutic concentrations. In reality, eliminating the first 2 VPA concentrations, which were subtherapeutic, made almost no difference. </p></fn><fn><p>
<sup>3</sup>Other scheduled oral medications included asenapine 10&#x02009;mg/day, naproxen 1000&#x02009;mg/day, omeprazole 20&#x02009;mg/day, trimethoprim/sulfamethoxazole 1600/320&#x02009;mg/day (for skin breakdown over swollen lower extremities), and trazodone 100&#x02009;mg/day.</p></fn><fn><p>
<sup>4</sup>Other scheduled oral medications included asenapine 15&#x02009;mg/day, gabapentin 900&#x02009;mg/day, lisinopril 10&#x02009;mg/day, meloxicam 15&#x02009;mg/day, metoprolol 50&#x02009;mg/day, omeprazole 20&#x02009;mg/day, trimethoprim/sulfamethoxazole 1600/320&#x02009;mg/day (for skin breakdown over swollen lower extremities), tramadol 150&#x02009;mg/day, and trazodone 150&#x02009;mg/day.</p></fn><fn><p>
<sup>5</sup>Other scheduled oral medications included asenapine 15&#x02009;mg/day, gabapentin 900&#x02009;mg/day, lisinopril 10&#x02009;mg/day, meloxicam 15&#x02009;mg/day, metoprolol 50&#x02009;mg/day, omeprazole 20&#x02009;mg/day, tramadol 150&#x02009;mg/day, and trazodone 150&#x02009;mg/day.</p></fn><fn><p>
<sup>6</sup>Other scheduled oral medications included asenapine 15&#x02009;mg/day, furosemide 40&#x02009;mg/day, gabapentin 900&#x02009;mg/day, lisinopril 10&#x02009;mg/day, metoprolol 50&#x02009;mg/day, omeprazole 20&#x02009;mg/day, tramadol 150&#x02009;mg/day, and trazodone 150&#x02009;mg/day.</p></fn><fn><p>
<sup>7</sup>Other scheduled oral medications included asenapine 15&#x02009;mg/day, furosemide 20&#x02009;mg/day, gabapentin 1200&#x02009;mg/day, lisinopril 10&#x02009;mg/day, metoprolol 50&#x02009;mg/day, omeprazole 20&#x02009;mg/day, tramadol 200&#x02009;mg/day, and trazodone 150&#x02009;mg/day.</p></fn><fn><p>
<sup>8</sup>Other scheduled oral medications included asenapine 15&#x02009;mg/day, furosemide 20&#x02009;mg/day, gabapentin 1200&#x02009;mg/day, metoprolol 50&#x02009;mg/day, omeprazole 20&#x02009;mg/day, tramadol 200&#x02009;mg/day, and trazodone 150&#x02009;mg/day.</p></fn><fn><p>
<sup>9</sup>Other scheduled oral medications included asenapine 15&#x02009;mg/day, furosemide 20&#x02009;mg/day, gabapentin 1200&#x02009;mg/day, metoprolol 50&#x02009;mg/day, omeprazole 20&#x02009;mg/day, polyethylene glycol 17&#x02009;g/day, tramadol 200&#x02009;mg/day, and trazodone 150&#x02009;mg/day.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>VPA C/D ratio in Case 3.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Day<sup>1</sup></th><th align="center" colspan="5" rowspan="1">VPA</th><th align="center" colspan="2" rowspan="1">Phenytoin</th></tr><tr><th align="center" rowspan="1" colspan="1">Formulation</th><th align="center" rowspan="1" colspan="1">Dose<sup>1</sup> (mg/day)</th><th align="center" rowspan="1" colspan="1">Concentration (<italic>&#x003bc;</italic>g/mL)</th><th align="center" rowspan="1" colspan="1">C/D ratio</th><th align="center" rowspan="1" colspan="1">C/D ratio &#x000d7; 1000</th><th align="center" rowspan="1" colspan="1">Dose (mg/day)</th><th align="center" rowspan="1" colspan="1">Concentration (<italic>&#x003bc;</italic>g/mL)</th></tr></thead><tbody><tr><td align="center" colspan="8" rowspan="1">All 137 VPA concentrations (C/D ratio &#x000d7; 1000: mean &#x000b1; SD = 8 &#x000b1; 3.5, range = 3&#x02013;20)</td></tr><tr><td align="center" colspan="8" rowspan="1">70 therapeutic<sup>2</sup> VPA concentrations (C/D ratio &#x000d7; 1000: mean &#x000b1; SD = 9 &#x000b1; 3.4, range = 5&#x02013;18)</td></tr><tr><td align="left" rowspan="1" colspan="1">1<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3375</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">33<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3375</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">62<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa </td><td align="center" rowspan="1" colspan="1">3375</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">86<sup>3</sup></td><td align="center" rowspan="1" colspan="1">Concentrate</td><td align="center" rowspan="1" colspan="1">3350</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">117<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3450</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">0.012 </td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">147<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3375</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">162<sup>3</sup></td><td align="center" rowspan="1" colspan="1">Concentrate</td><td align="center" rowspan="1" colspan="1">3450</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">174<sup>3</sup></td><td align="center" rowspan="1" colspan="1">Concentrate</td><td align="center" rowspan="1" colspan="1">3450</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">177<sup>3</sup></td><td align="center" rowspan="1" colspan="1">Concentrate</td><td align="center" rowspan="1" colspan="1">3450</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">189<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3375</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">0.011 </td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">202<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3750</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">208<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4125</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">212<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa </td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">244<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">274<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">307<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">310<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1"> 0</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">313<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">316<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">320<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">324<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">4500</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">335<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa </td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">350<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">398<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">400<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa </td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">430<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">439<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">470<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">502<sup>3</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">530<sup>4</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">559<sup>4</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">590<sup>5</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">621<sup>6</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">635<sup>6</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5000</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">646<sup>6</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">681<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">713<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 7</td></tr><tr><td align="left" rowspan="1" colspan="1">734<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">5250</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">762<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">6000</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">770<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa </td><td align="center" rowspan="1" colspan="1">6000</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">798<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">6000</td><td align="center" rowspan="1" colspan="1"> 23</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">806<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">6000</td><td align="center" rowspan="1" colspan="1"> 32</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">817<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 36</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">200</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">831<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 43</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 5</td></tr><tr><td align="left" rowspan="1" colspan="1">838<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 47</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">846<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 24</td><td align="center" rowspan="1" colspan="1">0.003 </td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">852<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 35</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">860<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 51</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">866<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 42</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 3</td></tr><tr><td align="left" rowspan="1" colspan="1">888<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 71</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">890<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 81</td><td align="center" rowspan="1" colspan="1">0.011 </td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">916<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 45</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 7</td></tr><tr><td align="left" rowspan="1" colspan="1">919<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7500</td><td align="center" rowspan="1" colspan="1"> 46</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 7</td></tr><tr><td align="left" rowspan="1" colspan="1">929<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">8250</td><td align="center" rowspan="1" colspan="1"> 43</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">943<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 43</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">950<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 50</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">957<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 75</td><td align="center" rowspan="1" colspan="1">0.008 </td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">964<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 37</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">971<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 28</td><td align="center" rowspan="1" colspan="1">0.003 </td><td align="center" rowspan="1" colspan="1"> 3</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">972<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 44</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">979<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 64</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">985<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 38</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">989<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 50</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">992<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 59</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">999<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 54</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">1014<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 35</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">1020<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 42</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 5</td></tr><tr><td align="left" rowspan="1" colspan="1">1029<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 43</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 7</td></tr><tr><td align="left" rowspan="1" colspan="1">1035<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">1039<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 54</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 1</td></tr><tr><td align="left" rowspan="1" colspan="1">1042<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 77</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">1056<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">0.011 </td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">1062<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 39</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">1064<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 47</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 7</td></tr><tr><td align="left" rowspan="1" colspan="1">1070<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 56</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">1080<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 51</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">1091<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 54</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">1098<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 63</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1"> 6 </td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">1105<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 49</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">1112<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 47</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">1119<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 51</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 6</td></tr><tr><td align="left" rowspan="1" colspan="1">1133<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 91</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 7</td></tr><tr><td align="left" rowspan="1" colspan="1">1148<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 50</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1163<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 40</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">1168<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 62</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">1175<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 63</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1182<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">1184<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 61</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">1189<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 56</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">1196<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">14000</td><td align="center" rowspan="1" colspan="1">133</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">1210<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 67</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1217<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 65</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">1224<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 87</td><td align="center" rowspan="1" colspan="1">0.008 </td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">1231<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 70</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1245<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 65</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">1252<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 97</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1"> 9</td></tr><tr><td align="left" rowspan="1" colspan="1">1259<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 77</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1266<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 56</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">1273<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 97</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">1280<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 60</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">1287<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 39</td><td align="center" rowspan="1" colspan="1">0.004 </td><td align="center" rowspan="1" colspan="1"> 4</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">1294<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">1301<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 48</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">1307<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 72</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1316<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 54</td><td align="center" rowspan="1" colspan="1">0.005 </td><td align="center" rowspan="1" colspan="1"> 5</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1322<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 71</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1329<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 75</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1336<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 98</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">1344<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 93</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">1350<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 65</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">1357<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 58</td><td align="center" rowspan="1" colspan="1">0.006 </td><td align="center" rowspan="1" colspan="1"> 6</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">1364<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 73</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">1371<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">1373<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">1378<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 89</td><td align="center" rowspan="1" colspan="1">0.008 </td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">1386<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 97</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">1392<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 72</td><td align="center" rowspan="1" colspan="1">0.007 </td><td align="center" rowspan="1" colspan="1"> 7</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">1393<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 87</td><td align="center" rowspan="1" colspan="1">0.008 </td><td align="center" rowspan="1" colspan="1"> 8</td><td align="center" rowspan="1" colspan="1">460</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">1394<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">122</td><td align="center" rowspan="1" colspan="1">0.012 </td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">230</td><td align="center" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1">1395<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">3500</td><td align="center" rowspan="1" colspan="1"> 37</td><td align="center" rowspan="1" colspan="1">0.011 </td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1"> 0</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">1399<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">130</td><td align="center" rowspan="1" colspan="1">0.012 </td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">1406<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1"> 94</td><td align="center" rowspan="1" colspan="1">0.009 </td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">1413<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">126</td><td align="center" rowspan="1" colspan="1">0.012 </td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">1420<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">10500</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="left" rowspan="1" colspan="1">1427<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">6000</td><td align="center" rowspan="1" colspan="1"> 59</td><td align="center" rowspan="1" colspan="1">0.010 </td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1">1435<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1"> 5</td></tr><tr><td align="left" rowspan="1" colspan="1">1440<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 86</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1"> 8</td></tr><tr><td align="left" rowspan="1" colspan="1">1444<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1"> 82</td><td align="center" rowspan="1" colspan="1">0.009</td><td align="center" rowspan="1" colspan="1"> 9</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">1448<sup>8</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">9000</td><td align="center" rowspan="1" colspan="1">147</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">1454<sup>7</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7000</td><td align="center" rowspan="1" colspan="1"> 93</td><td align="center" rowspan="1" colspan="1">0.013</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">1457<sup>9</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7000</td><td align="center" rowspan="1" colspan="1">138</td><td align="center" rowspan="1" colspan="1">0.020</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">1461<sup>10</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7000</td><td align="center" rowspan="1" colspan="1"> 72</td><td align="center" rowspan="1" colspan="1">0.010</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1470<sup>11</sup></td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7000</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">1478</td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7000</td><td align="center" rowspan="1" colspan="1">113</td><td align="center" rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1"> 7</td></tr><tr><td align="left" rowspan="1" colspan="1">1483</td><td align="center" rowspan="1" colspan="1">ECDVNa</td><td align="center" rowspan="1" colspan="1">7000</td><td align="center" rowspan="1" colspan="1"> 97</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1"> 6</td></tr></tbody></table><table-wrap-foot><fn><p>C/D: concentration-to-dose; ECDVNa: enterocoated divalproex sodium; VPA: valproic acid.</p></fn><fn><p>
<sup>1</sup>After day 1420, VPA dose was guided more by physical comfort than VPA concentrations; therefore, these latter days were eliminated to calculate the Pearson correlation between day of admission and VPA dose, which was <italic>r</italic> = 0.92 (<italic>p</italic> &#x0003c; 0.001); VPA dose remained very high in a partial correlation while controlling for VPA concentration: <italic>r</italic> = 0.89 (<italic>p</italic> &#x0003c; 0.001). This is compatible with a progressive autoinduction indicating, at least with dose range, that it was necessary to increase the dose as the duration lengthened. When all values (including those after day 1420) were used to calculate correlations, the <italic>r</italic> values were, not surprisingly, slightly reduced both for the total correlation of <italic>r</italic> = 0.83 (<italic>p</italic> &#x0003c; 0.001) and the partial correlation of <italic>r</italic> = 0.78 (<italic>p</italic> &#x0003c; 0.001). </p></fn><fn><p>
<sup>2</sup>50&#x02013;100&#x02009;<italic>&#x003bc;</italic>g/mL concentrations are considered therapeutic concentrations. As this patient has too many nontherapeutic concentrations, it may be better to compare with other patients using only the VPA therapeutic concentrations. </p></fn><fn><p>
<sup>3</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, mesoridazine 200&#x02009;mg/day, lorazepam 6&#x02009;mg/day, and risperidone 12&#x02009;mg/day.</p></fn><fn><p>
<sup>4</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, lorazepam 6&#x02009;mg/day, and risperidone 12&#x02009;mg/day.</p></fn><fn><p>
<sup>5</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day, lorazepam 6&#x02009;mg/day, and risperidone 4&#x02009;mg/day.</p></fn><fn><p>
<sup>6</sup>Other scheduled oral medications included benztropine 4&#x02009;mg/day and lorazepam 6&#x02009;mg/day.</p></fn><fn><p>
<sup>7</sup>Other scheduled oral medications included lorazepam 6&#x02009;mg/day.</p></fn><fn><p>
<sup>8</sup>Other scheduled oral medications included lorazepam 6&#x02009;mg/day and trazodone 150&#x02009;mg/day.</p></fn><fn><p>
<sup>9</sup>Other scheduled oral medications included lorazepam 4&#x02009;mg/day.</p></fn><fn><p>
<sup>10</sup>Other scheduled oral medications included lorazepam 3&#x02009;mg/day.</p></fn><fn><p>
<sup>11</sup>Other scheduled oral medications included lorazepam 1&#x02009;mg/day.</p></fn></table-wrap-foot></table-wrap></floats-group></article>